Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

NEKTAR THERAPEUTICS

NKTR · Nasdaq · CIK 0000906709 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

15 Form 4 transaction lines observed in the same window
10 sales · 5 option, withholding, award, gift or other lines

Last qualifying purchaseNo qualifying purchase is present in the local Form 4 history.

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
ROBIN HOWARD WPresident & CEO
▼▼▼▼
Zalevsky JonathanChief R&D Officer
▼▼▼▼
WHITFIELD ROY ADirector
○
GREER R SCOTTDirector
○
CHESS ROBERTDirector
○
Brainard DianaDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot.—

Recent Form 4 activity

0Purchases
16Sales
10Other Form 4 lines
20SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING10 sale line(s) · context only
OTHER5 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
6,968,325
Previous report
5,735,633
Avg daily volume
1,851,733
Days to cover
3.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

No qualifying code P equity purchase is present in the local Form 4 history.

Form 4 evidence

26 transaction lines in the latest 365-day window; 285 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-23WHITFIELD ROY AAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23GREER R SCOTTAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23CHESS ROBERTAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (24 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-23WHITFIELD ROY AAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23GREER R SCOTTAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23CHESS ROBERTAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23Brainard DianaAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-09-23Ajer Jeffrey RobertAward / grant (A)Common Stock2,000USD 0.00USD 0SEC filing ↗
2026-08-18Zalevsky JonathanSale (S)Common Stock186USD 71.98USD 13,388SEC filing ↗
2026-08-18ROBIN HOWARD WSale (S)Common Stock418USD 71.98USD 30,088SEC filing ↗
2026-06-30Zalevsky JonathanSale (S)Common Stock5,681USD 70.00USD 397,670SEC filing ↗
2026-06-17ROBIN HOWARD WSale (S)Common Stock10,000USD 61.19USD 611,880SEC filing ↗
2026-06-16ROBIN HOWARD WSale (S)Common Stock10,000USD 60.32USD 603,176SEC filing ↗
2026-06-15Zalevsky JonathanSale (S)Common Stock5,538USD 60.71USD 336,212SEC filing ↗
2026-05-19Zalevsky JonathanSale (S)Common Stock199USD 65.51USD 13,036SEC filing ↗
2026-05-19ROBIN HOWARD WSale (S)Common Stock444USD 65.51USD 29,086SEC filing ↗
2026-02-18Zalevsky JonathanSale (S)Common Stock180USD 73.00USD 13,140SEC filing ↗
2026-02-18ROBIN HOWARD WSale (S)Common Stock423USD 73.00USD 30,879SEC filing ↗
2026-01-20Zalevsky JonathanSale (S)Common Stock3,867USD 35.67USD 137,936SEC filing ↗
2025-12-22Zalevsky JonathanAward / grant (A)Common Stock6,250USD 0.00USD 0SEC filing ↗
2025-12-22ROBIN HOWARD WAward / grant (A)Common Stock21,667USD 0.00USD 0SEC filing ↗
2025-11-25Zalevsky JonathanSale (S)Common Stock1,157USD 54.28USD 62,802SEC filing ↗
2025-11-25Wilson Mark AndrewSale (S)Common Stock630USD 54.28USD 34,196SEC filing ↗
2025-11-25ROBIN HOWARD WSale (S)Common Stock2,207USD 54.28USD 119,796SEC filing ↗
2025-11-21Zalevsky JonathanAward / grant (A)Common Stock2,666USD 0.00USD 0SEC filing ↗
2025-11-21Wilson Mark AndrewAward / grant (A)Common Stock1,903USD 0.00USD 0SEC filing ↗
2025-11-21ROBIN HOWARD WAward / grant (A)Common Stock7,110USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNKTR
CIK0000906709
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history285 transaction lines from 2020-02-06 to 2026-09-23
0 P purchase lines · 189 S sale lines · 96 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.